2017 Press Releases

Webcast ImageWebcast
Piper Jaffray Healthcare Conference (Live)
11/28/17 at 11:00 a.m. ET
Piper Jaffray Healthcare Conference
Tuesday, November 28, 2017 11:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Evercore ISI Biopharma Catalyst/Deep Dive Conference (Live)
11/29/17 at 11:45 a.m. ET
Evercore ISI Biopharma Catalyst/Deep Dive Conference
Wednesday, November 29, 2017 11:45 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/21/17Audentes Therapeutics Announces Publication of Data from RECENSUS, a Retrospective Medical Record Review of Patients With X-Linked Myotubular Myopathy
SAN FRANCISCO, Nov. 21, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the publication of "A Multicenter, Retrospective Medical Record Review of X-Linked Myotubular Myopathy: The RECENSUS Study," in Muscle & Nerve.  This publication from RECENSUS, a study sponsored by Audentes, expands upon the da... 
Printer Friendly Version
11/16/17Audentes Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO, Nov. 16, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences: Piper Jaffray Healthcare Conference November 28, 2017, 11:00 am ET Lotte New York Palace, New York, NY ... 
Printer Friendly Version
11/14/17Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
- Completed enrollment of the first dose cohort of ASPIRO, the Phase 1 / 2 clinical study of AT132 to treat X-Linked Myotubular Myopathy (XLMTM) - AT132 has been well-tolerated by all patients with no significant treatment-related safety signals to date - Plan to report preliminary clinical data from ASPIRO in early January 2018 SAN FRANCISCO, Nov. 14, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercia... 
Printer Friendly Version
11/13/17Audentes Therapeutics Announces MHRA Approval of Clinical Trial Authorisation Application for AT342 to Treat Crigler-Najjar Syndrome
SAN FRANCISCO, November 13, 2017 / PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Clinical Trial Authorisation (CTA) application for AT342, the Company's gene therapy product candidate being developed to treat Crigl... 
Printer Friendly Version
11/07/17Audentes Therapeutics to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 14, 2017
-- Conference Call and Webcast to Follow -- SAN FRANCISCO, Nov. 7, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference call to report its third quarter 2017 financial results and provide a corporate update on Tuesday, November 14, 2017. The conference call will be held at 4:30 p.m. ET, after the marke... 
Printer Friendly Version
10/03/17Audentes Therapeutics Announces MHRA Approval of Clinical Trial Authorisation Application for AT132 to Treat X-Linked Myotubular Myopathy
... 
Printer Friendly Version
09/27/17Audentes Therapeutics Announces Rare Pediatric Disease and Fast Track Designations for AT132 for the Treatment of X-Linked Myotubular Myopathy
Preliminary data from ASPIRO, the Phase 1 / 2 study of AT132, expected to be available in the fourth quarter of 2017 SAN FRANCISCO, Sept. 27, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease and Fast Track designati... 
Printer Friendly Version
09/21/17Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy
Preliminary data from ASPIRO expected to be available in the fourth quarter of 2017 SAN FRANCISCO, Sept. 21, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has commenced dosing of patients in ASPIRO, a Phase 1 / 2 clinical trial of AT132 for the treatment of X-Linked Myotubular Myopathy (XLMT... 
Printer Friendly Version
09/19/17Audentes Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO, Sept. 19, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences: LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology September 27, 2017, 11:30 am ET Lot... 
Printer Friendly Version
08/10/17Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
- Audentes plans to initiate Phase 1 / 2 clinical trials for AT132 to treat X-Linked Myotubular Myopathy (XLMTM) and AT342 to treat Crigler-Najjar Syndrome in the third quarter of 2017 - Audentes plans to report preliminary clinical data from Phase 1 / 2 studies of AT132 and AT342 by the end of 2017 - In April 2017, strengthened balance sheet with a follow-on financing of $80.6 million in net proceeds SAN FRANCISCO, Aug. 10, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOL... 
Printer Friendly Version
07/18/17Audentes Therapeutics Announces Appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe
SAN FRANCISCO, July 18, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe. Dr. Mavilio will be based in Paris. "We are extremely pleased to add Fulvio to the Audentes team," stated Matthew R. Patterson, President and Chief Exe... 
Printer Friendly Version
06/28/17Audentes Therapeutics Announces Participation in Upcoming Investor Conferences
SAN FRANCISCO, June 28, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced its participation in the following upcoming investor conferences: Piper Jaffray GenomeRx Symposium Panel: Gene Therapy – Tackling Manufacturing July 11, 2017, 11:20 am ET The Lotte New York Palace, New York Wedbush PacGrow Health... 
Printer Friendly Version
06/13/17Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors
SAN FRANCISCO, June 13, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of Jennifer Jarrett to its board of directors. "We are very pleased to welcome Jen to our board of directors," stated Matthew R. Patterson, President and Chief Executive Officer. "Jen is an accomplished life scienc... 
Printer Friendly Version
05/11/17Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
- INDs for AT132 to treat X-Linked Myotubular Myopathy (XLMTM) and AT342 to treat Crigler-Najjar Syndrome are active - Strengthened balance sheet with a follow-on financing of $80.7 million in net proceeds - Preliminary clinical data from phase 1 / 2 studies of AT132 and AT342 anticipated in the fourth quarter of 2017 SAN FRANCISCO, May 11, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy pr... 
Printer Friendly Version
05/10/17Audentes Therapeutics to Present At Upcoming Investor Conferences
SAN FRANCISCO, May 10, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences: Bank of America Merrill Lynch 2017 Health Care Conference Gene Therapy & Editing Panel May 17, 2017, ... 
Printer Friendly Version
05/08/17Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer
SAN FRANCISCO, May 8, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer.  Dr. Gray joined Audentes in 2014 as Vice President, Research and Development, and has successfully built and led teams across the Company's molecula... 
Printer Friendly Version
05/03/17Audentes Therapeutics Announces Presentation of Data at the American Society of Gene and Cell Therapy Annual Meeting
SAN FRANCISCO, May 3, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that data related to its product candidates AT132 for the treatment of X-linked Myotubular Myopathy, and AT342 for the treatment of Crigler Najjar Syndrome, will be presented at the 20th Annual Meeting of the American Society of Gene... 
Printer Friendly Version
04/18/17Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO, April 18, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the pricing of its underwritten public offering of 5,200,000 shares of its common stock at a price to the public of $14.50 per share before underwriting discounts and commission. The gross proceeds to Audentes from the offering, before dedu... 
Printer Friendly Version
04/17/17Audentes Therapeutics Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, April 17, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it intends to offer and sell 4,750,000 shares of its common stock in an underwritten public offering.  In addition, Audentes intends to grant the underwriters a 30-day option to purchase up to an additional 712,500 shares of common sto... 
Printer Friendly Version
04/17/17Audentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
SAN FRANCISCO, April 17, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present a corporate overview at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day in Boston, MA.  The presentation is scheduled fo... 
Printer Friendly Version
04/03/17Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT132 to Treat X-Linked Myotubular Myopathy
- Preliminary data from ASPIRO, the planned Phase 1 / 2 Clinical Study of AT132, expected in fourth quarter of 2017 SAN FRANCISCO, April 3, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for AT... 
Printer Friendly Version
03/20/17Audentes Therapeutics Announces Presentation Of Data From RECENSUS, A Medical Chart Review Of Patients With X-Linked Myotubular Myopathy (XLMTM)
Data confirm and expand understanding of significant medical burden associated with XLMTM SAN FRANCISCO, March 20, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that data from RECENSUS, a medical chart review of patients with X-linked Myotubular Myopathy (XLMTM), will be presented at the 2017 Muscular Dys... 
Printer Friendly Version
03/09/17Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
- IND for AT132 to treat X-Linked Myotubular Myopathy (XLMTM) submitted - IND for AT342 to treat Crigler-Najjar Syndrome active - Large scale, internal cGMP manufacturing established to support advancement of pipeline programs - Preliminary clinical data from Phase 1 / 2 studies of AT342 and AT132 anticipated in the fourth quarter of 2017 SAN FRANCISCO, March 9, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and com... 
Printer Friendly Version
03/01/17Audentes Therapeutics Announces Commencement of LUSTRO, a Clinical Assessment and Phase 1 / 2 Run-in Study of Patients with Crigler-Najjar Syndrome
- LUSTRO intended to serve as a longitudinal baseline and within-patient control for VALENS, the planned Phase 1 / 2 study of AT342 for the treatment of Crigler-Najjar Syndrome SAN FRANCISCO, March 1, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the commencement of LUSTRO, a prospective study desig... 
Printer Friendly Version
02/07/17Audentes Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO, Feb. 7, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences: LEERINK Partners 6th Annual Global Healthcare Conference February 15, 2017, 9:00 am ET Lotte New York Palace... 
Printer Friendly Version
02/01/17Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome
Preliminary data from VALENS, the Phase 1 / 2 Clinical Study of AT342, expected by end of 2017 SAN FRANCISCO, Feb. 1, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for AT342, the Company's gen... 
Printer Friendly Version
01/12/17Gene therapy’s big surprise may be in an old South S.F. warehouse
... 
Printer Friendly Version
01/09/17Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance
- Filed IND with the FDA for AT342 in Crigler-Najjar Syndrome - Large Scale Internal cGMP Manufacturing Capability Expected to be Established for Entire Pipeline of Four Programs - Preliminary Clinical Data from Lead Programs Expected by Year-End SAN FRANCISCO, Jan. 9, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseas... 
Printer Friendly Version
01/04/17Audentes Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 4, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will provide a corporate overview and 2017 outlook at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.  The presentation is scheduled for Tuesday, Januar... 
Printer Friendly Version